Glucagon-like peptide-1 receptor agonists tied to higher thyroid cancer risk in first year of treatment
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...
thecardiologyadvisor.com6h
GLP-1 Receptor Agonists Tied to Risks and Benefits Beyond Weight Loss
For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.
Becker's Hospital Review23h
GLP-1 drug approvals: A breakdown
Discover the FDA-approved indications for GLP-1 receptors, including diabetes, weight loss, and cardiovascular disease. Learn brand-name and generic options.
Medscape10d
Glucagon-Like Peptide-1 Inhibits Blood-Brain Glucose Transfer in Humans
Objective. Glucagon-like peptide-1 (GLP-1) has many effects on glucose homeostasis, and GLP-1 receptors are broadly represented in many tissues including the brain. Recent research in rodents ...
Endocrinology Advisor1d
Real-World Effectiveness of GLP-1 RA vs DPP4i in Moderate to Severe CKD Explored
In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).
Websites selling compounded GLP-1 RAs often misinform consumers, research reveals
Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...
Renal & Urology News6d
GLP-1 Receptor Agonists May Have Broader Range of Benefits, Risks
With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...
Endocrinology Advisor1d
Select GLP-1 Receptor Agonists Reduce Risk of CKD Progression, ESKD, and MACE
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...
Medscape5d
The Glucagonostatic and Insulinotropic Effects of Glucagon-like Peptide 1 Contribute Equally to its Glucose-lowering Action
Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...
Monthly Prescribing Reference7d
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
The analysis included 98,147 GLP-1 RA users and approximately 2.49 million DPP-4i users, with a median follow-up ranging from 1.8 to 3 years. HealthDay News — Glucagon-like peptide 1 receptor ...
emjreviews.com2d
GLP-1 Receptor Agonists Linked to Behavioural Side Effects
A RECENT population-based analysis has highlighted potential behavioural side effects associated with Glucagon-like peptide 1 ...
Ulster University1mon
Targeting glucagon-like peptides for the treatment of diabetes and obesity
Adherence to glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study. Diabetes Obes Metab. 2024 Nov;26(11):5239-5250. Sridhar A, Khan D, Elliott JA, ...